Testing a new injection to control moderate to severe asthma

Plain-English translation of NCT07372287 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a medication called , given as an injection under the skin, to see if it can help people with moderate to severe asthma that isn't well-controlled with standard treatments. Researchers will compare the new medication to a placebo (a dummy injection) to understand how well this treatment works and how safe it is over one year.

Many people with moderate to severe asthma still have symptoms and flare-ups even when taking strong controller medications. This trial exists to see if this new treatment can better control asthma and prevent serious attacks in patients who need additional help.

Do you qualify?

You likely qualify if…

you are at least 18 years old and no older than 80
you have been diagnosed with asthma for at least one year
you have had at least one serious asthma attack in the past 12 months
you are already taking medium-to-high dose asthma controller medicines (combined with at least one other asthma drug) and have kept them stable for at least one month
you have moderate-to-severe asthma symptoms despite your current treatment

You likely don't qualify if…

you have chronic obstructive pulmonary disease (COPD) or other lung diseases besides asthma
you have a history of cancer or serious immune system problems
you have had a recent serious infection or are currently taking antibiotics for an active infection
you are already taking other biologic medications for asthma or similar conditions
you have severe heart disease or uncontrolled diabetes

What participation looks like

You would visit the study clinic multiple times over about 4 months of screening and evaluation, then receive either the new medication or a placebo injection for 52 weeks (one year). During this time, you'll have regular visits to check how well the treatment works, monitor your asthma control, and watch for any side effects. After the year of treatment ends, you'll have a final 12-week safety follow-up period with additional check-ins.

AI-generated summary from trial data · Jun 29, 2026 · Not medical advice

Trial locations(1 site)

China

Ruijin Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, Shanghai Municipality